PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-95.21%
Negative revenue growth while AXSM stands at 0.00%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-116.81%
Negative gross profit growth while AXSM is at 2614.27%. Joel Greenblatt would examine cost competitiveness or demand decline.
-52.01%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-52.01%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-52.47%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-43.48%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-43.48%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
7.17%
Share count expansion well above AXSM's 1.98%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
7.17%
Diluted share count expanding well above AXSM's 1.98%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
582.93%
Positive OCF growth while AXSM is negative. John Neff would see this as a clear operational advantage vs. the competitor.
577.68%
Positive FCF growth while AXSM is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9508.05%
Positive long-term OCF/share growth while AXSM is negative. John Neff would see a structural advantage in sustained cash generation.
131.96%
Positive OCF/share growth while AXSM is negative. John Neff might see a comparative advantage in operational cash viability.
210.81%
Positive 3Y OCF/share CAGR while AXSM is negative. John Neff might see a big short-term edge in operational efficiency.
88.12%
Positive 10Y CAGR while AXSM is negative. John Neff might see a substantial advantage in bottom-line trajectory.
91.00%
Positive 5Y CAGR while AXSM is negative. John Neff might view this as a strong mid-term relative advantage.
67.11%
Positive short-term CAGR while AXSM is negative. John Neff would see a clear advantage in near-term profit trajectory.
1963.85%
Equity/share CAGR of 1963.85% while AXSM is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
-27.97%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
5.99%
Below 50% of AXSM's 109.96%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
63.35%
Asset growth at 50-75% of AXSM's 103.88%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
5.97%
BV/share growth above 1.5x AXSM's 1.41%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
1244.16%
Debt growth far above AXSM's 87.29%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
6.71%
R&D dropping or stable vs. AXSM's 25.48%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
86.34%
SG&A growth well above AXSM's 21.23%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.